Učitavanje...

Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach

Treatment options for myeloma continue to develop at a rapid pace, and it is becoming increasingly challenging to determine the optimal therapeutic approaches because demonstrating a clear survival benefit now requires many years of follow-up. The detection of minimal residual disease (MRD) is recog...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cytometry B Clin Cytom
Glavni autori: Rawstron, Andy C., Paiva, Bruno, Stetler-Stevenson, Maryalice
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7511969/
https://ncbi.nlm.nih.gov/pubmed/26202864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cyto.b.21272
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!